Market revenue in 2023 | USD 303.2 million |
Market revenue in 2030 | USD 2,165.2 million |
Growth rate | 32.4% (CAGR from 2023 to 2030) |
Largest segment | Drug optimization & repurposing |
Fastest growing segment | Drug Optimization & Repurposing |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Drug Optimization & Repurposing, Preclinical Testing |
Key market players worldwide | International Business Machines Corp, Exscientia PLC ADR, Alphabet Inc Class A, Benevolent AI, Recursion Pharmaceuticals Inc Class A, Aitia, BioSymetrics, Euretos, Berg, Atomwise, Insitro |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to artificial intelligence in drug discovery market will help companies and investors design strategic landscapes.
Drug optimization & repurposing was the largest segment with a revenue share of 53.73% in 2023. Horizon Databook has segmented the Asia Pacific artificial intelligence in drug discovery market based on drug optimization & repurposing, preclinical testing covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing patient pool, growing acceptance of cloud computing, and rising number of government programs supporting AI are primary factors expected to drive the market. In addition, increasing number of biopharmaceutical firms are applying AI to modernize the drug discovery process.
AI application is found in the field of diagnostics. For instance, in 2017, China’s Tencent introduced an AI-driven diagnostic medical imaging facility, called AI Medical Innovation System (AIMIS). The technology exhibited 90% and 95% accuracy.
for initial diagnoses of esophageal & lung cancers, respectively. In April 2020, Cyclica announced a multiyear & multiproject collaboration with the Genome Institute of Singapore (GIS). The collaboration aims to carry out research efforts extending.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific artificial intelligence in drug discovery market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific artificial intelligence in drug discovery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account